pH-Responsive Biomaterials for Tumor-Targeted Drug Delivery and Controlled Degradation
DOI:
https://doi.org/10.61173/1d07km53Keywords:
pH-responsive biomaterials, tumor microen-vironment, controllable degradationAbstract
Cancer has become a major threat to human health, and its treatment is still hampered by challenges such as poor drug targeting and significant toxic side effects. In recent years, the acidic nature of the tumor microenvironment (TME) has offered new avenues for tumor-targeted therapy, and pH-responsive materials have garnered considerable attention for their selective release capabilities. A variety of pH-responsive drug delivery systems have been developed, including polymeric micelles, hydrogels, liposomes, and acid-labile chemical bond conjugation systems, designed to ensure stability in the bloodstream and specific drug release within the acidic TME. However, limitations remain, such as insufficient spatiotemporal precision in drug release and restricted delivery efficiency. This review systematically summarizes the research advancements in pH-responsive materials for tumor-targeted therapy, analyzes the acidic basis of the TME and its implications for material design, encompassing response mechanisms, commonly used materials, structural designs, and multiple response strategies. Furthermore, targeting mechanisms, controlled release platforms, personalized designs, and theranostic integration strategies in precision drug delivery are discussed. A detailed overview of controllable degradation is also presented, ranging from degradation mechanisms to regulation strategies, highlighting the importance of material metabolic safety in clinical translation. This study provides a reference for the structural design and functional integration of future pH-responsive intelligent materials.
References
[1] Khalaf N, El-Serag H B, Abrams H R, et al. Burden of pancreatic cancer: From epidemiology to practice. Clinical Gastroenterology and Hepatology, 2021, 19(5): 876–884.
[2] Liu N, Wang X, Wang Z, et al. Nanomaterials-driven in situ vaccination: A novel frontier in tumor immunotherapy. Journal of Hematology & Oncology, 2025, 18(1): 45.
[3] Gillies R J, Verduzco D, Gatenby R A. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nature Reviews Cancer, 2008, 8(5): 329–340.
[4] Wagner W, Ciszewski W M, Kania K D. Lactic acid in the tumor microenvironment—Friend or foe?. Cells, 2021, 10(1): 117.
[5] Couto N, Wood J, Barber J. The role of glutathione reductase and related enzymes on cellular redox homoeostasis network. Free Radical Biology and Medicine, 2016, 95: 27–42.
[6] Overall C M, Kleifeld O. Tumour microenvironment – opinion: Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nature Reviews Cancer, 2006, 6(3): 227–239.
[7] Bae Y, Park K. Targeted drug delivery to tumors: Myths, Dean&Francis Haobo Wang reality and possibility. Journal of Controlled Release, 2011, 153(3): 198–205.
[8] Lee E S, Na K, Bae Y H. Doxorubicin loaded pH-sensitive liposomes: Characterization, in vitro and in vivo evaluation. Journal of Controlled Release, 2005, 103(2): 405–418.
[9] Chenite A, Chaput C, Wang D, et al. Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials, 2000, 21(21): 2155–2161.
[10] Zhang W, Huang T, Ren Y, et al. A multifunctional chitosan composite aerogel for PPCPs adsorption. Carbohydrate Polymers, 2022, 298: 120102.
[11] Blebea N M, Pușcașu C, Vlad R A, et al. Chitosan-Based Gel Development: Extraction, Gelation Mechanisms, and Biomedical Applications. Gels, 2025, 11(4): 275.
[12] Cirillo G, Spizzirri U G, Curcio M, et al. Injectable hydrogels for cancer therapy over the last decade. Pharmaceutics, 2019, 11(9): 486.
[13] Zhang Y, et al. Enzyme-Responsive Nanoparticles for Anti- Tumor Drug Delivery. Frontiers in Chemistry, 2020, 8: 647.
[14] Liu Y, et al. Polymer-Based Hydrogels Applied in Drug Delivery: An Overview. Gels, 2023, 9(8): 637.
[15] Guo X, et al. Dimeric Drug Polymeric Micelles with Acid- Active Tumor Targeting and FRET-Indicated Drug Release. arXiv preprint, 2024.
[16] Zhao Y, et al. Ultrasound-triggered Herceptin liposomes for breast cancer therapy. Scientific Reports, 2021, 11: 86860.
[17] Guo X, Wang L, Duval K, et al. Dimeric Drug Polymeric Micelles with Acid-Active Tumor Targeting and FRET-Traceable Drug Release. Advanced Materials, 2018, 30(3): 1705436.
[18] Kuo Y C, Chen Y C. Targeting delivery of etoposide to inhibit the growth of human glioblastoma multiforme using lactoferrin- and folic acid-grafted poly(lactide-co-glycolide) nanoparticles. International Journal of Pharmaceutics, 2015, 479(1): 138–149.
[19] Xu J, et al. Self-targeting visualizable hyaluronate nanogel for synchronized chemotherapy and photothermal therapy. Nano Research, 2020, 13(4): 1135–1145.
[20] Zhang L, et al. Sustained and long-term release of doxorubicin from PLGA nanoparticles for efficient cancer therapy. Pharmaceutics, 2020, 12(12): 1165.
[21] Yang C, Wang X, Yao X, et al. Matrix metalloproteinaseresponsive biodegradable hydrogel for targeted tumor therapy. Acta Biomaterialia, 2020, 101: 160–171.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.

This work is licensed under a Creative Commons Attribution 4.0 International License.
